ondansetron has been researched along with Arrhythmias, Cardiac in 17 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the risk of cardiac arrhythmias associated with ondansetron administration in the context of recent recommendations for identification of high-risk individuals." | 8.90 | Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "Ondansetron is a 5-HT₃ receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively." | 8.89 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. ( Doggrell, SA; Hancox, JC, 2013) |
| "To explore the risk of cardiac arrhythmias associated with ondansetron administration in the context of recent recommendations for identification of high-risk individuals." | 4.90 | Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "Ondansetron is a 5-HT₃ receptor antagonist commonly used as an antiemetic to prevent nausea and vomiting associated with anti-cancer drugs, cancer radiotherapy or postoperatively." | 4.89 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. ( Doggrell, SA; Hancox, JC, 2013) |
| "A wide variety of bradyarrhythmias and tachyarrhythmias occur following ingestion." | 2.45 | Management of yellow oleander poisoning. ( Rajapakse, S, 2009) |
| " Statistical analysis of dose-response showed the maximum mean difference in QTcF, compared to placebo and corrected for baseline (ddQTcF), was less than 10 milliseconds (ms) after an 8 mg IV dose and approximately 20 ms after the 32 mg dose, each infused over 15 minutes." | 1.40 | Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. ( Fang, L; Haberer, LJ; Hunt, TL; Ridgway, D; Russo, MW; Zuo, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L | 1 |
| Sun, H | 1 |
| Al-Khalil, M | 1 |
| Sack, A | 1 |
| Elson, R | 1 |
| Pleat, J | 1 |
| Wang, EHZ | 1 |
| Sunderland, S | 1 |
| Edwards, NY | 1 |
| Chima, NS | 1 |
| Yarnold, CH | 1 |
| Schwarz, SKW | 1 |
| Coley, MA | 1 |
| Freedman, SB | 2 |
| Finkelstein, Y | 2 |
| Gummin, DD | 1 |
| Moeller, JR | 1 |
| Drendel, AL | 1 |
| Frommeyer, G | 2 |
| Fischer, C | 2 |
| Ellermann, C | 2 |
| Dechering, DG | 2 |
| Kochhäuser, S | 2 |
| Lange, PS | 2 |
| Wasmer, K | 1 |
| Fehr, M | 2 |
| Eckardt, L | 2 |
| Darpo, B | 1 |
| Benson, C | 1 |
| Brown, R | 1 |
| Dota, C | 1 |
| Ferber, G | 1 |
| Ferry, J | 1 |
| Jarugula, V | 1 |
| Keirns, J | 1 |
| Ortemann-Renon, C | 1 |
| Pham, T | 1 |
| Riley, S | 1 |
| Sarapa, N | 1 |
| Ticktin, M | 1 |
| Zareba, W | 1 |
| Couderc, JP | 1 |
| Doggrell, SA | 1 |
| Hancox, JC | 1 |
| Patel, J | 1 |
| Uleryk, E | 1 |
| Rumantir, M | 1 |
| Lee, JH | 1 |
| Park, YH | 1 |
| Kim, JT | 1 |
| Kim, CS | 1 |
| Kim, HS | 1 |
| Zuo, P | 1 |
| Haberer, LJ | 1 |
| Fang, L | 1 |
| Hunt, TL | 1 |
| Ridgway, D | 1 |
| Russo, MW | 1 |
| Tricco, AC | 1 |
| Soobiah, C | 1 |
| Hui, W | 1 |
| Antony, J | 1 |
| Struchkov, V | 1 |
| Hutton, B | 1 |
| Hemmelgarn, B | 1 |
| Moher, D | 1 |
| Straus, SE | 1 |
| Rajapakse, S | 1 |
| Miller, DR | 1 |
| Baguley, WA | 1 |
| Hay, WT | 1 |
| Mackie, KP | 1 |
| Cheney, FW | 1 |
| Cullen, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blinded, Randomized Control Trial of Prophylactic Ondansetron in a Post-operative Cardiac Surgery Population for Post-operative Nausea and Vomiting[NCT02966041] | 186 participants (Actual) | Interventional | 2018-03-06 | Completed | |||
| Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery[NCT04853147] | Phase 3 | 1,154 participants (Actual) | Interventional | 2021-04-27 | Completed | ||
| Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis[NCT05716854] | Phase 1 | 44 participants (Actual) | Interventional | 2023-03-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ondansetron and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Humans; Nausea; Ondansetron; Randomized Co | 2013 |
Droperidol- and ondansetron-induced life-threatening arrhythmias.
Topics: Aged; Antiemetics; Arrhythmias, Cardiac; Droperidol; Fatal Outcome; Female; Humans; Long QT Syndrome | 2013 |
Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis.
Topics: Antiemetics; Arrhythmias, Cardiac; Emergency Treatment; Humans; Monitoring, Physiologic; Ondansetron | 2014 |
Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiogr | 2015 |
Management of yellow oleander poisoning.
Topics: Antibodies, Blocking; Antidotes; Antiemetics; Arrhythmias, Cardiac; Blood Pressure; Charcoal; Digoxi | 2009 |
2 trials available for ondansetron and Arrhythmias, Cardiac
10 other studies available for ondansetron and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Arrhythmias, Cardiac; Burns; Comorbidity; Drug Int | 2020 |
Route of ondansetron administration and ventricular arrhythmias.
Topics: Antiemetics; Arrhythmias, Cardiac; Humans; Ondansetron; Risk | 2017 |
Reply.
Topics: Arrhythmias, Cardiac; Humans; Ondansetron | 2017 |
Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Domperidone; Drug Interactions; Erythromycin; Fema | 2018 |
The effect of sevoflurane and ondansetron on QT interval and transmural dispersion of repolarization in children.
Topics: Adolescent; Anesthetics, Inhalation; Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Co | 2014 |
Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Topics: Adolescent; Adult; Antiemetics; Arrhythmias, Cardiac; Computer Simulation; Cross-Over Studies; Dose- | 2014 |
Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone.
Topics: Animals; Antiemetics; Arrhythmias, Cardiac; Domperidone; Dose-Response Relationship, Drug; Female; O | 2017 |
Arrhythmogenic potential of antiemetics: perspectives on risk-benefits.
Topics: Antiemetics; Arrhythmias, Cardiac; Atrial Fibrillation; Droperidol; Electrocardiography; Humans; Ind | 2003 |
Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide.
Topics: Adult; Antiemetics; Arrhythmias, Cardiac; Female; Humans; Injections, Intravenous; Male; Metoclopram | 1997 |